// App-Quantinova.ai

1942 : Anlotinib Shows Potent Antileukemia Effects in B-Cell Acute Lymphocytic Leukemia through the Blockage of Angiogenic Related Pathways

Researchers

Presenter

  • Qiuling Chen

Principal Investigators

  • Yuelong Jiang

  • Qinwei Chen

  • Long Liu

  • Bing Xu

Medical Centers

  • Department of Pathology, School of Basic Medicine, Fujian Medical University, Fuzhou, China

  • Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • Lung Cancer

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Platelet derived growth factor

  • Platelet-derived growth factor receptor

  • Fibroblast growth factor receptor

  • Fibroblast growth factor receptor 3

  • Kinase Insert Domain Receptor

  • Serine/threonine-protein kinase mTOR

  • Vascular endothelial growth factor A

  • PI3K/AKT

Drug/Treatment

  • anlotinib

  • L-Tyrosine

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved